Highlights From Day 3 of ASCOGU25

The 2025 symposium, which took place from February 13th to 15th, featured high-impact science, multidisciplinary expertise, and evidence-based practices in GU oncology.

Our team at OncoDaily has selected a few posts from Day 3 of this event that you should not miss!

ASCO:

“Final day of GU25! Kicking things off with Oral Abstract Session C: Renal Cell Cancer—looking forward to the latest insights and discussions.”

Neeraj Agarwal:

“Outstanding talk and discussion on emerging treatment landscape of mRCC Kidney Cancer by Tian Zhang, emphasizes the need to personalize treatment in mRCC kidney cancer. Next generation trials below.”

Julie Gralow:

“Fun catching up with GU friends and colleagues at ASCOGU25.”

Tom Powles:

“SAMETA: the 1st biomarker-driven R3 papillary RCC study #GU25 . CALYPSO is the phase 2 data supporting it. RR PFS and OS in the MET-driven group looks promising for durva/savolitinib. Dr Frankie Jackson-Spence also presents baseline and dynamic ctDNA analysis. A new biomarker in PRCC?”

Emre Yekedüz:

“Durvalumab + Savolitinib shows strong efficacy in MET-driven advanced papillary RCC + promising ctDNA-based prognostic insights:

• Response Rate: 34% (all aPRC), 59% (MET-driven)
• Median PFS: 8.4 vs. 16.7 months (ITT vs. MET-driven)
• Median OS: 18.3 vs. 27.4 months (ITT vs. MET-driven)
• ctDNA+ at baseline = worse OS
• ctDNA clearance linked to improved PFS
• Durvalumab + Savolitinib continues to show promise in MET-driven PRC—ongoing SAMETA trial will further validate!”

Maite Bourlon:

“Happy to be ASCOGU25: Failure to immunotherapy in Renal Cell Cancer. What’s Next? Mechanisms of IO resistance Oligoprogression SBRT and surgery treatment sequencing.

Multidisciplinary panel – Raquibul Hannan, Matt Campbell, Viraj Master, Kathryn Hacker Gessner and Ballas.”

Katy Beckermann:

“Another enlightening talk from Turajlic Lab (Samra Turajlic)! Breaking down the complexity of biomarker development in RCC, linking genotype to phenotypic changes. Showing us they are tackling the challenge head-on with cutting-edge multi-modal approaches!”

Tian Zhang:

“Great last session at ASCOGU25 – interactive case-based discussions for hard-to-treat kidney cancer. Good to see Raquibul Hannan representing UTSW Radiation Oncology on expert panel, along with friends.”

Michael Hofman:

“PSMA PET/CT or radioligand therapy is mentioned 600 times in the ASCOGU25 prostate cancer abstracts (advanced and localized).

I think around 1 in 5 of abstracts contain PSMA! Amazing to see the uptake of this new technology over the last 10 years. ENZA-P was my highlight from the meeting – photo of the ANZUP trials
team lead by Louise Emmett.”

Sia Daneshmand:

“Excellent discussion by Clint Cary, following Axel Heidenreich’s long-term follow up of the COTRIMS trial. Surgery for early metastatic seminoma. Appreciate continuous efforts to improve on already excellent curative outcomes with RPLND alone.”

Hedyeh Ebrahimi:

“ Fascinating data from Wenxin (Vincent) Xu at ASCOGU25!

• Early decrease in KIM-1 (≥30%) after 3 weeks of Nivo+Ipi leads to predictive of long-term efficacy
• Higher baseline KIM-1 leads to worse OS/PFS
• Prospective validation needed.”

Julian Chavarriaga:

“Xiaofan Lu discussed racial disparities in RCC histology and outcomes from the French Kidney Cancer Research Network (UroCCR-191) :

• > ccRCC in non-black (69% vs 48%)
• >non ccRCC in black pts (45% vs 24%)
• 3x > pRCC and 6x > FH-deficient RCC in black pts
• Black patients: <age dx, earlier cT stage
• MVA analysis revealed that race is not an independent prognostic feature in patients with RCC.”

Karine Tawagi:

“A few GU25 highlights presenting our research on

• socioeconomic disparities, real-world patterns and outcomes in mUC
• treatment sequencing for 2L mUC post EV/P
• low-dose abi cost/adherence
•  touring SF”

Regina Barragan-Carrillo:

“Some of the most powerful discussions at ASCOGU25 didn’t just teach me about science – they taught me about courage. The courage to ask hard questions, challenge norms, and embrace vulnerability in pursuit of better care. Inspired by Tian Zhang, Elizabeth Plimack and Tanya Dorff.

Science has no nations – just a shared mission: push boundaries, cure more.”

Shilpa Surasi:

“Honored to represent SNMMI Prostate Cancer outreach working group at my first ASCOGU25. Proud to be working with the best of the best: Chad Tang, Pavlos Msaouel, Brian F. Chapin, Ana Aparicio and it was great meeting new colleagues – Angela Jia, Louise Emmett and many more.”

Jordan Ciuro:

“Updates of Casdatifan in previously treated ccRCC? Phase 1 ARC-20 safety and efficacy at ASCOGU25. Key Takeaways; in N=93 Casdatifan:

• At dose 100mg qday ORR in 33%
• Well tolerated
• Pending updates from phase 3 PEAK-1 trial evaluating 100 mg casdatifan with cabozantinib vs cabozantinib + placebo”

Avi Harisingani:

“An eventful end to the vacation block! Grateful to have had the opportunity to present our research at ASCOGU25, and as always a great time catching up with friends and mentors!”

ASCO:

“That’s a wrap on GU25! Thank you to everyone who made this year’s meeting a success. From groundbreaking science to insightful discussions, your contributions are driving progress in GU oncology. See you next year!”